ArticleJournal of pharmacy & bioallied sciences2025
Cognitive Impairment in Post-COVID-19 Patients: A Prospective Neuropsychological Evaluation Study.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive impairments, often termed "brain fog," have emerged as prevalent sequelae among individuals recovering from COVID-19. Despite increasing recognition, systematic neuropsychological evaluation data remain limited. Methods: A prospective observational study was conducted between February 2023 and December 2024 in a tertiary care neurorehabilitation center. One hundred twenty post-COVID-19 patients (mean age 44.6 ± 11.3 years; 58.3% male) presenting with cognitive complaints at least 3 months after recovery were recruited. Patients underwent evaluation using the Montreal Cognitive Assessment (MoCA), Trail Making Test A and B (TMT-A, TMT-B), and Digit Span Test. A control group of 60 age- and education-matched individuals without prior COVID-19 served as comparison. Statistical analysis included independent t-tests, chi-square tests, and multivariate logistic regression ( Results: Cognitive impairment (MoCA score <26) was observed in 66.7% of post-COVID-19 participants compared to 15.0% of controls ( Conclusion: Cognitive deficits are common in post-COVID-19 patients, particularly affecting attention, processing speed, and working memory. Structured cognitive screening and rehabilitation may be essential components of long-term COVID-19 care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.